Trade Zentalis Pharmaceuticals - ZNTL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.34 |
| Open | 4.35 |
| 1-Year Change | -82.94% |
| Day's Range | 4.25 - 4.57 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 4.31 | 0.12 | 2.86% | 4.19 | 4.39 | 4.12 |
| Jul 24, 2024 | 4.27 | 0.24 | 5.96% | 4.03 | 4.54 | 4.03 |
| Jul 23, 2024 | 4.17 | 0.32 | 8.31% | 3.85 | 4.18 | 3.82 |
| Jul 22, 2024 | 3.96 | 0.25 | 6.74% | 3.71 | 3.97 | 3.57 |
| Jul 19, 2024 | 3.66 | -0.20 | -5.18% | 3.86 | 3.95 | 3.65 |
| Jul 18, 2024 | 3.91 | -0.34 | -8.00% | 4.25 | 4.31 | 3.87 |
| Jul 17, 2024 | 4.24 | -0.06 | -1.40% | 4.30 | 4.73 | 4.17 |
| Jul 16, 2024 | 4.52 | 0.57 | 14.43% | 3.95 | 4.52 | 3.92 |
| Jul 15, 2024 | 3.95 | -0.10 | -2.47% | 4.05 | 4.05 | 3.81 |
| Jul 12, 2024 | 3.92 | -0.01 | -0.25% | 3.93 | 4.22 | 3.79 |
| Jul 11, 2024 | 3.95 | 0.00 | 0.00% | 3.95 | 4.12 | 3.84 |
| Jul 10, 2024 | 3.90 | -0.24 | -5.80% | 4.14 | 4.23 | 3.85 |
| Jul 9, 2024 | 4.20 | 0.13 | 3.19% | 4.07 | 4.43 | 3.94 |
| Jul 8, 2024 | 4.14 | 0.61 | 17.28% | 3.53 | 4.22 | 3.53 |
| Jul 5, 2024 | 3.59 | 0.21 | 6.21% | 3.38 | 3.62 | 3.20 |
| Jul 3, 2024 | 3.43 | -0.11 | -3.11% | 3.54 | 3.67 | 3.42 |
| Jul 2, 2024 | 3.54 | -0.49 | -12.16% | 4.03 | 4.09 | 3.39 |
| Jul 1, 2024 | 4.15 | 0.25 | 6.41% | 3.90 | 4.22 | 3.90 |
| Jun 28, 2024 | 4.06 | -0.09 | -2.17% | 4.15 | 4.15 | 3.97 |
| Jun 27, 2024 | 4.16 | 0.10 | 2.46% | 4.06 | 4.26 | 3.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zentalis Pharmaceuticals Company profile
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).
| Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com